Skip to main content
ASBP logo

Aspire Biopharma Holdings, Inc. (ASBP) Stock Price & Analysis

Aspire Biopharma Holdings, Inc. (ASBP) — MoonshotScore 23/100 (Weak band), calculated Nov 18, 2026. Price $7.65 (-3.04%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$7.65 −$0.24 (-3.04%)

Aspire Biopharma Holdings, Inc. · ASBP · NASDAQ

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company focused on developing and marketing novel sublingual delivery mechanisms. Their lead product, Instaprin, aims to address cardiology emergencies and pain management through a fast-acting, soluble aspirin formulation.

Price as of Nov 19, 2026

Key Statistics

23 of 100

MoonshotScore v2 · Aspire Biopharma Holdings (ASBP)

Weak
Business Quality Poor (18)
Financial Safety Fortress (84)
Valuation Rich (38)
Growth Durability Flat (42)
Momentum Quiet (41)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet, but bottom-tier quality and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Flat; Momentum: Quiet.

  • quarterly revenue $63,103 (Q2 FY2026, quarter ended Jun 30, 2026)
  • Altman Z -3.47 · Piotroski F 5

Holding back: weak fundamentals

Helping: balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ASBP (57 recorded, newest six shown)
RecordedScoreBand
21Weak
21Weak
21Weak
21Weak
23Weak
23Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$7.65
Change on the day-3.04%
52-week range$0.11 – $205.20
Price / earnings (trailing)-0.10
Shares traded on the day9.7K

Price & events

Other perspectives

Council score for Aspire Biopharma Holdings (ASBP): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Strong
Valuation Weak
Growth Durability Neutral
Momentum Neutral

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Strong
Gross Margin Negative

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Aspire Biopharma Holdings (ASBP), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Aspire Biopharma Holdings, Inc. (ASBP) is listed on NASDAQ. It employs 2 people and is led by Kraig T. Higginson. In Q2 FY2026 it reported revenue of $63,103 and net income of -$1M.

2 · Latest results

What do the latest results show for Aspire Biopharma Holdings (ASBP)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $63,103.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$63,103-$1M-$1.22 (diluted)
Q1 FY2026$28,353-$3M-$2.16 (diluted)
Q4 FY2025$4,261-$5M-$3.15 (diluted)
Q3 FY2025$1,941-$2M-$1.49 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Aspire Biopharma Holdings (ASBP)?

Short answer · as of

The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals. The distress and quality screens read Altman Z -3.47 · Piotroski F 5. Trailing ratios: ROA -81.6% · current ratio 7.99 · earnings yield -126.6%.

5 · Peer comparison

How does Aspire Biopharma Holdings compare with its peers?

Short answer

Aspire Biopharma Holdings's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
BeOne Medicines Ltd. (ONC) Same industry, near in market value$403.60 Nov 18, 2026$46.1B96 5-pillar Nov 18, 2026
Cullinan Therapeutics, Inc. (CGEM) Same industry, near in market value$9.07 Nov 19, 2026$589M51 5-pillar Nov 18, 2026
Galecto, Inc. (DMRA) Same industry, near in market value$24.30 Nov 19, 2026$1.50B50 5-pillar Nov 18, 2026
111, Inc. (YI) Same industry, near in market value$2.51 Nov 19, 2026$22.1M40 5-pillar Nov 18, 2026
High Tide Inc. (HITI) Same industry, near in market value$2.29 Nov 19, 2026$204M36 5-pillar Nov 18, 2026
Satellos Bioscience Inc. Common Stock (MSLE) Same industry, near in market value$5.80 Nov 19, 2026$123M32 5-pillar Nov 18, 2026
Kyntra Bio, Inc. (KYNB) Same industry, near in market value$1.83 Nov 19, 2026$7.41M32 5-pillar Nov 18, 2026
Rein Therapeutics, Inc. (RNTX) Same industry, near in market value$0.37 Nov 19, 2026$31.7M30 5-pillar Nov 18, 2026
PetMed Express, Inc. (PETS) Same industry, near in market value$0.90 Nov 18, 2026$20.0M29 5-pillar Nov 18, 2026
Aspire Biopharma Holdings (ASBP) — this page$7.65—23
LifeMD, Inc. (LFMDP) Same industry, near in market value$18.75 Nov 19, 2026$133M22 5-pillar Nov 18, 2026
Pomdoctor Limited (POM) Same industry, near in market value$1.61 Nov 19, 2026$57.9M21 5-pillar Nov 18, 2026
Neuphoria Therapeutics Inc. (NEUP) Same industry, near in market value$2.28 Nov 18, 2026$12.3M21 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ASBP in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ASBP in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Investor Questions: ASBP Stock

These answers are editorial: 1 of these 9 answers is drawn from the ASBP research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ASBP?

ASBP carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company focused on developing and marketing novel sublingual delivery mechanisms.

Is ASBP a good stock to buy?

Stock Expert AI does not rate ASBP buy, sell or hold. Aspire Biopharma Holdings, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ASBP stock price today?

The last price recorded for Aspire Biopharma Holdings, Inc. (ASBP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for ASBP?

Aspire Biopharma Holdings, Inc. faces several key risks, including regulatory hurdles, competition, and financial constraints. The company's success depends on obtaining regulatory approvals for its sublingual drug formulations, which can be a lengthy and uncertain process.

What are the key factors to evaluate for ASBP?

Aspire Biopharma Holdings, Inc. (ASBP) holds a MoonshotScore in the low range. This could provide access to additional funding, resources, and market expertise. Not financial advice.

How frequently does ASBP data refresh on this page?

ASBP's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ASBP's recent stock price performance?

Aspire Biopharma Holdings, Inc. (ASBP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel sublingual drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ASBP overvalued or undervalued right now?

Aspire Biopharma Holdings, Inc. (ASBP) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of ASBP?

Fractional-share availability for Aspire Biopharma Holdings, Inc. (ASBP) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.